What question did this study set out to answer?

This research aims to assess the 12-month treatment persistence and clinical outcomes of subcutaneous infliximab in patients with inflammatory bowel disease.

January 23, 2026

P0977Treatment persistence and efficacy of subcutaneous infliximab monotherapy in patients with Inflammatory Bowel Disease: a real-world setting

Key Points

This research aims to assess the 12-month treatment persistence and clinical outcomes of subcutaneous infliximab in patients with inflammatory bowel disease.
Conducted a retrospective observational cohort study at a tertiary center.
Collected baseline clinical, biochemical, and endoscopic data at the start of treatment and at 12 months.
Utilized logistic regression analysis to determine predictors for treatment discontinuation.
91.1% treatment persistence at 12 months among 101 adult patients.
Sustained or improved clinical outcomes observed in 99.0% of patients.
High persistence seen in biochemical and endoscopic measures, with infliximab trough levels showing consistency.

Abstract

Abstract Background Subcutaneous infliximab (SC-IFX) offers an alternative to intravenous therapy with potential advantages in treatment persistence, medication burden and patient adherence. This study evaluated 12-month treatment persistence along with clinical, biochemical, and endoscopic outcomes among patients with inflammatory bowel disease (IBD) established on SC-IFX monotherapy. Methods A retrospective observational cohort study was conducted at a tertiary centre. Baseline clinical (CDAI or partial Mayo score), biochemical (C-reactive protein, albumin, haemoglobin, faecal calprotectin, IFX trough levels) and endoscopic data were collected at index of SC-IFX commencement and at 12-months. Logistic regression analysis was used to identify predictors of treatment discontinuation. Results 101 adult patients were on SC-IFX monotherapy, 57 (56.4%) had Crohn’s Disease and 44 (43.6%) had Ulcerative Colitis. Treatment persistence at 12 months was 91.1% (92/101), with sustained or improved clinical (100/101, 99.0%), biochemical (CRP (87/101, 88.1%), albumin (97/101, 96.0%), haemoglobin (100/101, 99.0%), faecal calprotectin (87/95, 91.6%), infliximab trough levels (86/94, 91.5%) and endoscopic activity (90/93, 96.8%) outcomes at 12 months. Multivariate regression analysis only identified prior ileal resection as an independent predictor of treatment discontinuation at 12-months. Conclusion • Real-world study demonstrating high 12-month persistence of SC-IFX monotherapy with and maintenance of clinical, biochemical, and endoscopic outcomes at 12 months. • Stable pharmacokinetic profile (higher, more consistent trough levels) likely underpins durability and may reduce need for immunomodulators. • Clinical relevance: potential practical long-term maintenance option, avoids immunomodulator risks (infection, malignancy), improves convenience, reduces infusion burden. • Limitations: retrospective single-centre design, modest sample size. • Future directions: longer-term outcomes, larger multicentre studies, exploration of predictors of treatment discontinuation and pharmacogenomics. Conflict of interest: Dr. Mansoor, Matthew: No conflict of interest Subhaharan, Deloshaan: No conflict of interest James, Rayshelle: No conflict of interest Kakkadasam Ramaswamy, Pradeep: No conflict of interest Mohsen, Waled: No conflict of interest

Mark Helpful

Bookmark

Relay